Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy

Journal of Urology

Volumn 161, Issue 4, 1999, Pages 1238-1243

  Brewster, Simon F ^a   Oxley, Jon D ^b   Trivella, Marialena ^b   Abbott, Clive D ^b   Gillatt, David A ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Biopsy; p53; Prostatectomy; Prostatic neoplasms; Proto oncogene proteins C bcl 2

Indexed keywords

HERMES ANTIGEN; PROTEIN BCL 2; PROTEIN P53; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; PROTEIN EXPRESSION; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032853502     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61646-X     Document Type: Article

References (21)

1. Walsh, P. C., Partin, A. W. and Epstein, J. I.: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol., 152: 1831, 1994.
2. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
3. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol., 152: 1821, 1994.
4. Dillioglugil, O., Liebman, B. D., Katten, M. W., Seale-Hawkins, C., Wheeler, T. M. and Scardino, P. T.: Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology, 50: 93, 1997.
5. Frazier, H. A., Robertson, J. E., Humphrey, P. A. and Paulson, D. F.: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J. Urol., 148: 516, 1993.
6. Partin, A. W., Katten, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E., Scardino, P. T. and Pearson, J. D.: Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. J.A.M.A., 277: 1445, 1997.
7. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol., 156: 1511, 1996.
8. Umbas, R., Isaacs, W. B., Bringuier, P. P., Schaafsma H. E., Karthaus, H. F. M., Oosterhof, G. O. N., Debruyne, F. M. J. and Schalken, J. A.: Decreased E-cadherin expression is correlated with poor prognosis in patients with prostate cancer. Cancer Res., 54: 3929, 1994.
9. Noordzij, M. A., van Steenbrugge, G-J., Verkaik, N. S., Schroder, F. H. and van der Kwast, T. H.: The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin. Cancer Res., 3: 805, 1997.
10. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blochlinger, A., Gasser, T. C. and Mihatsch, M. J.: Prognostic significance of bcl-2 in clinically localized prostate cancer. Amer. J. Path., 148: 1557, 1996.
11. Byrne, R. L., Wilson-Horne, C. H., Robinson, M. C. and Neal, D. M.: The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Brit. J. Urol., 79: 190, 1997.
12. Matsushima, H., Kitamura, T., Goto, T., Hosaka, Y., Homma, Y. and Kawabe, K.: Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol., 158: 2278, 1997.
13. Kallakury, B. V., Yang, F., Figge, J., Smith, K. E., Kausik, S. J., Tacy, N. J., Fisher, H. A. G., Kaufman, R., Figge, H. and Ross, J. S.: Decreased levels of CD44 protein and mRNA in prostate carcinoma: correlation with tumor grade and ploidy. Cancer, 78: 1461, 1996.
14. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J. Amer. Stat. Assn., 53: 187, 1958.
15. Cox, D. R.: Regression models and life-tables (with discussion). J. Roy. Stat. Soc., 34: 187, 1972.
16. Olsson, C. A., deVries, G. M., Raffo, A. J., Benson, M. C., O'Toole, K., Cao, Y., Buttyan, R. E. and Katz, A. E.: Preoperative reverse-transcriptase polymerase chain reaction for prostate-specific antigen predicts treatment failure after radical prostatectomy. J. Urol., 155: 1557, 1996.
17. Kahn, D., Williams, R. D., Seldin, D. W., Libertino, J. A., Hirschhorn, M., Dreicer, R., Weiner, G. J., Bushnell, D. and Gulfo J.: Radioimmunoscintigraphy with 111indium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Urol., 152: 1490, 1994.
18. Brewster, S. F., Browne, S. and Brown, K. W.: Somatic allelic loss at the DCC, APC, p53 and nm23-H1 and tumor suppressor gene loci in human prostatic carcinoma. J. Urol., 151: 1073, 1994.
19. Theodorescu, D., Broder, S. R., Boyd, J. C., Mills, S. E. and Frierson H. F.: p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J. Urol., 158: 131, 1997.
20. Gao, A. C., Lou, W., Dong, J. T. and Isaacs, J. T.: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res., 57: 846, 1997.
21. Albertsen, P. C.: Computer modelling - what should we look for? J. Urol., 159: 943, 1998.